Last reviewed · How we verify
Interleukin
At a glance
| Generic name | Interleukin |
|---|---|
| Sponsor | University of Arkansas |
| Drug class | Non-Standardized Plant Allergenic Extract [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
- Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (PHASE1)
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (PHASE1)
- Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
- Neutralizing Interleukin (IL)-6 (PHASE2)
- KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (PHASE1)
- TREg Activation in the Treatment of the PELADE (Alopecia Areata) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interleukin CI brief — competitive landscape report
- Interleukin updates RSS · CI watch RSS
- University of Arkansas portfolio CI